BGC > Produktsuche > Lorlatinib (pf-06463922) | 1454846-35-5

Molecular Formula: C21H19FN6O2
Molecular Weight: 406.4129632

Assay : 99% min
Appearance : white powder

The third-generation ALK inhibitor can inhibit 9 mutations that are resistant to crizotinib, has a strong blood-brain barrier permeability, and has a strong brain effect.
It is especially suitable for patients with advanced NSCLC who are resistant to other ALKs.

Description:
Lorlatinib is an ATP-competitive ROS1/ALK inhibitor with potential antitumor activity. Lorlatinib binds to both ALK and ROS1 kinases, resulting in disruption of ALK- and ROS1-mediated signaling and inhibition of ALK- and ROS1-overexpressing tumor cells.

• Molecular Weight:406.421
• Boiling Point:675.0±55.0 °C at 760 mmHg
• Melting Point:184-187°C
• Purity:≥98%

Molecular Formula:
C21H19FN6O2
Canonical SMILES:
CC1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C
InChI:
InChI=1S/C21H19FN6O2/c1-11-15-7-13(22)4-5-14(15)21(29)27(2)10-16-19(17(8-23)28(3)26-16)12-6-18(30-11)20(24)25-9-12/h4-7,9,11H,10H2,1-3H3,(H2,24,25)/t11-/m1/s1
InChIKey:
IIXWYSCJSQVBQM-LLVKDONJSA-N
Appearance:
White Solid
Synonyms:
PF06463922; PF 06463922; PF-06463922; PF-6463922; PF6463922; PF 6463922; Loratinib.